neoplasm antigens

Summary

Summary: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.

Top Publications

  1. ncbi Cancer/testis antigens, gametogenesis and cancer
    Andrew J G Simpson
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Cancer 5:615-25. 2005
  2. ncbi A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    P van der Bruggen
    Ludwig Institute for Cancer Research, Brussels, Belgium
    Science 254:1643-7. 1991
  3. ncbi Frequent EpCam protein expression in human carcinomas
    Philip Th Went
    Institute for Pathology, University of Basel, Basel, Switzerland
    Hum Pathol 35:122-8. 2004
  4. ncbi The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis
    J S Munger
    Department of Medicine, and Kaplan Cancer Center, New York University School of Medicine, New York 10016 6402, USA
    Cell 96:319-28. 1999
  5. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
  6. ncbi Nova regulates brain-specific splicing to shape the synapse
    Jernej Ule
    Howard Hughes Medical Institute and Laboratory of Molecular Neuro Oncology, The Rockefeller University, New York, New York, USA
    Nat Genet 37:844-52. 2005
  7. pmc Natural selection of tumor variants in the generation of "tumor escape" phenotypes
    Hung T Khong
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Nat Immunol 3:999-1005. 2002
  8. ncbi Regulation of tumor pH and the role of carbonic anhydrase 9
    Pawel Swietach
    Department of Physiology, Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, Oxford OX1 3PT, UK
    Cancer Metastasis Rev 26:299-310. 2007
  9. pmc Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
    P Went
    Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Br J Cancer 94:128-35. 2006
  10. pmc A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
    E Stockert
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Exp Med 187:1349-54. 1998

Research Grants

Detail Information

Publications328 found, 100 shown here

  1. ncbi Cancer/testis antigens, gametogenesis and cancer
    Andrew J G Simpson
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Cancer 5:615-25. 2005
    ....
  2. ncbi A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    P van der Bruggen
    Ludwig Institute for Cancer Research, Brussels, Belgium
    Science 254:1643-7. 1991
    ..Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample...
  3. ncbi Frequent EpCam protein expression in human carcinomas
    Philip Th Went
    Institute for Pathology, University of Basel, Basel, Switzerland
    Hum Pathol 35:122-8. 2004
    ..Most soft-tissue tumors and all lymphomas were EpCam negative. It is concluded that anti-EpCam therapies, if proven to be successful, will have broad applications in a wide variety of carcinomas...
  4. ncbi The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis
    J S Munger
    Department of Medicine, and Kaplan Cancer Center, New York University School of Medicine, New York 10016 6402, USA
    Cell 96:319-28. 1999
    ..These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin...
  5. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  6. ncbi Nova regulates brain-specific splicing to shape the synapse
    Jernej Ule
    Howard Hughes Medical Institute and Laboratory of Molecular Neuro Oncology, The Rockefeller University, New York, New York, USA
    Nat Genet 37:844-52. 2005
    ..Validating a large set of Nova RNA targets has led us to identify a multi-tiered network in which Nova regulates the exon content of RNAs encoding proteins that interact in the synapse...
  7. pmc Natural selection of tumor variants in the generation of "tumor escape" phenotypes
    Hung T Khong
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Nat Immunol 3:999-1005. 2002
    ..Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies...
  8. ncbi Regulation of tumor pH and the role of carbonic anhydrase 9
    Pawel Swietach
    Department of Physiology, Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, Oxford OX1 3PT, UK
    Cancer Metastasis Rev 26:299-310. 2007
    ..We also review recent evidence that may suggest a role for CA9 in coordinating pH(i) among cells of large, unvascularized cell-clusters...
  9. pmc Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
    P Went
    Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Br J Cancer 94:128-35. 2006
    ....
  10. pmc A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
    E Stockert
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Exp Med 187:1349-54. 1998
    ..As the proportion of melanomas expressing NY-ESO-1 is 20-40% and only patients with NY-ESO-1(+) tumors have antibody, this would suggest that a high percentage of patients with NY-ESO-1(+) tumors develop an antibody response to NY-ESO-1...
  11. pmc Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha
    Meelad M Dawlaty
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cell 133:103-15. 2008
    ..Furthermore, mice with low amounts of RanBP2 are highly sensitive to tumor formation. Together, these data identify RanBP2 as a chromosomal instability gene that regulates Topo IIalpha by sumoylation and suppresses tumorigenesis...
  12. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  13. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  14. ncbi Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    ..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
  15. ncbi MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines
    Bing Yang
    Department of Dermatology and Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA
    Cancer Res 67:9954-62. 2007
    ..Because the expression of class I MAGE proteins is limited in normal tissues, inhibition of MAGE antigen expression or function represents a novel and specific treatment for melanoma and diverse malignancies...
  16. ncbi Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
    Ali O Gure
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8055-62. 2005
    ..We asked whether cancer-testis gene expression occurred coordinately, and whether it correlated with variables of disease and clinical outcome of non-small cell lung cancer (NSCLC)...
  17. ncbi Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
    Gilbert Spizzo
    Division of Hematology and Oncology, Innsbruck Medical University, Austria
    Gynecol Oncol 103:483-8. 2006
    ..To identify a potential molecular target and prognostic/predictive factor for EOC, we investigated in a retrospective study the prognostic value of Ep-CAM overexpression in EOC...
  18. ncbi Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema
    David G Morris
    Lung Biology Center, Department of Medicine, San Francisco General Hospital, San Francisco, California 94143, USA
    Nature 422:169-73. 2003
    ..Furthermore, we show that a functional alteration in the TGF-beta activation pathway affects susceptibility to this disease...
  19. pmc Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer
    I Songun
    Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Br J Cancer 92:1767-72. 2005
    ..Loss of Ep-CAM-expression identifies aggressive tumours especially in patients with stage I and II disease. This information may be helpful in selecting patients suitable for surgery or for additional treatment pre- or postoperatively...
  20. ncbi Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
    Sergei Kusmartsev
    H Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Immunol 172:989-99. 2004
    ..This study demonstrates a new mechanism of Ag-specific T cell inhibition mediated by ROS produced by ImCs in cancer...
  21. ncbi Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
    Immunol Rev 188:22-32. 2002
    ..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress...
  22. ncbi High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
    Gilbert Spizzo
    Division of Haematology and Oncology, University of Innsbruck, Innsbruck, Austria
    Breast Cancer Res Treat 86:207-13. 2004
    ....
  23. pmc MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents
    Martin Monte
    Laboratorio Nazionale del Consorzio Interuniversitario per le Biotecnologie, Area Science Park, Padriciano 99, 34012 Trieste, Italy
    Proc Natl Acad Sci U S A 103:11160-5. 2006
    ..In addition, combined trichostatin A/ET treatment in melanoma cells expressing high MAGE-A levels reestablishes p53 response and reverts the chemoresistance...
  24. ncbi CLIP identifies Nova-regulated RNA networks in the brain
    Jernej Ule
    Howard Hughes Medical Institute, Rockefeller University, New York, NY 10021, USA
    Science 302:1212-5. 2003
    ..Thus, CLIP reveals that Nova coordinately regulates a biologically coherent set of RNAs encoding multiple components of the inhibitory synapse, an observation that may relate to the cause of abnormal motor inhibition in POMA...
  25. ncbi Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 92:856-60. 2001
    ..There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression...
  26. ncbi Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival
    Meri Varga
    Division of Hematology and Oncology, University of Innsbruck, Innsbruck, Austria
    Clin Cancer Res 10:3131-6. 2004
    ..This retrospective study was designed to investigate the prognostic significance of epithelial cell adhesion molecule (Ep-CAM) overexpression in human gallbladder carcinoma...
  27. pmc Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    Jens Dannull
    Genitourinary Cancer Immunotherapy Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 115:3623-33. 2005
    ..Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact...
  28. ncbi An RNA map predicting Nova-dependent splicing regulation
    Jernej Ule
    Howard Hughes Medical Institute, New York, New York 10021, USA
    Nature 444:580-6. 2006
    ....
  29. ncbi Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance
    Alfred Zippelius
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research and Multidisciplinary Oncology Center, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Res 64:2865-73. 2004
    ..We show that both the lymph node and the tumor environments blunt T-cell effector functions and offer a rationale for the failure of tumor-specific responses to effectively counter tumor progression...
  30. ncbi Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors
    Chandra G Rao
    Immunicon Corporation, Huntingdon Valley, PA 19006, USA
    Int J Oncol 27:49-57. 2005
    ..This supports the hypothesis that this adhesion molecule is down-regulated on carcinoma cells in the circulation...
  31. ncbi A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
    Clin Cancer Res 9:1639-47. 2003
    ....
  32. ncbi Nuclear signalling by tumour-associated antigen EpCAM
    Dorothea Maetzel
    Clinical Cooperation Group Molecular Oncology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, and Head and Neck Research Dept, Ludwig Maximilians University of Munich, Germany
    Nat Cell Biol 11:162-71. 2009
    ..In patients, EpICD was found in nuclei of colon carcinoma but not of normal tissue. Nuclear signalling of EpCAM explains how EpCAM functions in cell proliferation...
  33. ncbi Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance
    Naofumi Yoshida
    Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University, Sapporo 060 0815, Japan
    Int J Oncol 28:1089-98. 2006
    ..MAGE-A4 expression in advanced group and T cell infiltration may provide prognostic information. Lastly, these CT antigens, especially MAGE-A4, may represent potential targets for cancer immunotherapy in patients with NSCLC...
  34. ncbi Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH
    Eliska Svastova
    Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
    FEBS Lett 577:439-45. 2004
    ..Our findings suggest that hypoxia regulates both expression and activity of CA IX in order to enhance the extracellular acidification, which may have important implications for tumor progression...
  35. ncbi Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer
    Johannes H A M Kaanders
    Department of Radiation Oncology, University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands
    Cancer Res 62:7066-74. 2002
    ..Pimonidazole and CA9 demonstrate concordant staining patterns, but the latter is a less specific marker for hypoxia...
  36. ncbi NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
    Yurika Sugita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita City, Osaka 565 0871, Japan
    Cancer Res 64:2199-204. 2004
    ....
  37. ncbi Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy
    Helen Y Wang
    The Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA
    Immunity 20:107-18. 2004
    ..These findings suggest that the presence of tumor-specific CD4(+) Treg cells at tumor sites may have a profound effect on the inhibition of T cell responses against cancer...
  38. ncbi Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH
    Johanna Chiche
    Institute of Developmental Biology and Cancer Research University of Nice, Centre National de la Recherche Scientifique UMR 6543, Centre A Lacassagne, 33 Avenue Valombrose, Nice, France
    Cancer Res 69:358-68. 2009
    ..Thus, hypoxia-induced CAIX and CAXII are major tumor prosurvival pH(i)-regulating enzymes, and their combined targeting shows that they hold potential as anticancer targets...
  39. ncbi Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin
    Eliska Svastova
    Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
    Exp Cell Res 290:332-45. 2003
    ..We conclude that CA IX has a capacity to modulate E-cadherin-mediated cell adhesion via interaction with beta-catenin, which could be of potential significance in hypoxia-induced tumor progression...
  40. ncbi Malignant effusions and immunogenic tumour-derived exosomes
    Fabrice Andre
    Departments of Clinical Biology, Immunology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet 360:295-305. 2002
    ..To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells...
  41. pmc MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma
    Jinyan Du
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Harvard Medical School, Boston, USA
    Am J Pathol 163:333-43. 2003
    ..Collectively, this study links three important melanoma antigens into a common transcriptional pathway regulated by MITF...
  42. ncbi The imprinted gene Magel2 regulates normal circadian output
    Serguei V Kozlov
    Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, USA
    Nat Genet 39:1266-72. 2007
    ....
  43. ncbi Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future
    Duxin Sun
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Surg Oncol 96:297-308. 2007
    ..PET/CT image-guided surgery only detects later stage disease. Fluorescence image-guided surgery using anti-TAG-72 antibodies may provide opportunities for intraoperative cancer detection of both gross and occult tumors...
  44. pmc Symbiotic bacteria direct expression of an intestinal bactericidal lectin
    Heather L Cash
    Center for Immunology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Science 313:1126-30. 2006
    ..We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships...
  45. ncbi Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer
    A Giatromanolaki
    Tumour and Angiogenesis Research Group, Department of Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece
    Cancer Res 61:7992-8. 2001
    ..The expression of CA9 is linked to the expression of a constellation of proteins involved in angiogenesis, apoptosis inhibition, and cell-cell adhesion disruption, which explains the strong association of CA9 with poor outcome...
  46. ncbi Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment
    J Pastorek
    Institute of Virology, Slovak Academy of Sciences, Bratislava
    Oncogene 9:2877-88. 1994
    ..In addition, the analysis of biological consequences of MN expression of NIH3T3 cells provides the evidence in favour of MN protein involvement in control of cell proliferation and transformation...
  47. ncbi Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival
    Edwin P Hui
    Departments of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Clin Cancer Res 8:2595-604. 2002
    ....
  48. pmc RAGE signaling in inflammation and arterial aging
    Li Lin
    Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, 21224, USA
    Front Biosci (Landmark Ed) 14:1403-13. 2009
    ..This review attempts to provide a comprehensive summary on both recent findings and missing pieces of the RAGE puzzle...
  49. ncbi The role of tumor stroma in the interaction between tumor and immune system
    Thomas Blankenstein
    Max Delbruck Center for Molecular Medicine, Robert Rossle Strasse 10, 13092 Berlin, Germany
    Curr Opin Immunol 17:180-6. 2005
    ..These cytokines inhibit tumor-induced angiogenesis, probably through different cellular targets...
  50. pmc Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer
    B Kate Dredge
    Laboratory of Molecular Neuro Oncology, Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10021, USA
    Mol Cell Biol 23:4687-700. 2003
    ....
  51. pmc CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients
    J L Pujol
    Montpellier Academic Hospital, Hopital Arnaud de Villeneuve, avenue du Doyen Giraud, 34295 Montpellier Cedex 5, France
    Br J Cancer 90:2097-105. 2004
    ..In conclusion CYFRA 21-1 might be regarded as a putative co-variable in analysing NSCLC outcome inasmuch as a high serum level is a significant determinant of poor prognosis whatever the planned treatment...
  52. pmc Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 112:1876-85. 2008
    ..PRAME CTLs were generated almost exclusively from the naive T-cell compartment, and clonal analysis showed these cells could have high alphabetaTCR-peptide avidity. PRAME CTLs or vaccines may thus be of value for patients with CML...
  53. ncbi Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
    H Ikeda
    Cellular Genetics Unit, Universite Catholique de Louvain, Brussels, Belgium
    Immunity 6:199-208. 1997
    ....
  54. pmc Can urinary exosomes act as treatment response markers in prostate cancer?
    Paul J Mitchell
    Section of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Velindre Cancer Centre, Whitchurch, Cardiff, UK
    J Transl Med 7:4. 2009
    ..Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy...
  55. pmc Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells
    Charles De Smet
    Ludwig Institute for Cancer Research, Brussels Branch, 74 avenue Hippocrate, B1200 Brussels, Belgium
    Mol Cell Biol 24:4781-90. 2004
    ..We conclude that the site-specific hypomethylation of MAGE-A1 in tumor cells relies on a transient process of demethylation followed by a persistent local inhibition of remethylation due to the presence of transcription factors...
  56. ncbi Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
    Anna K Palucka
    Baylor Institute for Immunology Research, Sammons Cancer Center, 3434 Live Oak, Dallas, TX 75204, USA
    J Immunother 29:545-57. 2006
    ..Thus, the present results justify the design of larger follow-up studies to assess the clinical response to DC vaccines loaded with killed allogeneic tumor cells in patients with metastatic melanoma...
  57. pmc DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX
    Milota Kaluzova
    Department of Microbiology and Molecular Genetics, University of California at Irvine, College of Medicine, Irvine 92717, USA
    Mol Cell Biol 24:5757-66. 2004
    ..A model outlining the quantitative relationship between p53, HIF-1alpha, and CAIX is presented...
  58. ncbi Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance
    Peter Jantscheff
    Kantonsspital Basel, Department of Research, Basel, Switzerland
    J Clin Oncol 21:3638-46. 2003
    ..The aim of our study was to evaluate the prognostic relevance of CEACAM6, CEACAM1, and CEA tissue expression in patients with CRC...
  59. pmc Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
    E Jager
    Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, 60488 Frankfurt, Germany
    J Exp Med 191:625-30. 2000
    ..Further, the therapeutic efficacy of active immunization using antigenic HLA class I-restricted peptides may be improved by adding HLA class II-presented epitopes...
  60. ncbi Tumor associated antigen recognition by autologous serum in patients with breast cancer
    Feng Qian
    Department of Biology, Indiana University, Bloomington, IN 47405, USA
    Int J Mol Med 15:137-44. 2005
    ..These clones did not react with sera from a panel of 25 healthy adult individuals. Our results demonstrate the utility of the SEREX approach for the identification of potential tumor associated antigens in human breast cancer...
  61. pmc Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:6458-62. 1994
    ....
  62. ncbi Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma
    Matthew H T Bui
    Departments of Urology, University of California Los Angeles, California 90095 1738, USA
    J Urol 171:2461-6. 2004
    ..The natural history of renal cell carcinoma (RCC) is complex and not entirely explained by conventional prognostic factors. In this study we evaluated the prognostic value of carbonic anhydrase IX (CAIX) and Ki67 to predict survival in RCC...
  63. ncbi Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion
    Naomi Robertson
    Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 64:6160-5. 2004
    ..Thus, CAIX plays an important role in the growth and survival of tumor cells under normoxia and hypoxia, making it a potential target for cancer therapy, but is not involved in invasion...
  64. ncbi Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis
    C Schick
    Department of Pediatrics, The Harvard Medical School, Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
    Biochemistry 37:5258-66. 1998
    ....
  65. ncbi Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape
    Yuichi Nakamura
    First Department of Medicine, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita ku, Sapporo 060 8638, Japan
    Cancer Sci 95:260-5. 2004
    ..The expression and distribution of RCAS1 may be involved in malignant transformation, tumor progression, histological type and tumor escape from host immune surveillance in gastric cancer...
  66. ncbi Squamous cell carcinoma antigen in human liver carcinogenesis
    M Guido
    Department of Diagnostic Medical Sciences and Special Therapies, Universitè degli Studi di Padova, Italy
    J Clin Pathol 61:445-7. 2008
    ..Squamous cell carcinoma antigen (SCCA) is a serine protease inhibitor that can be overexpressed in hepatocellular carcinoma (HCC) at both molecular and protein level, but no data are available on its expression in pre-malignant stages...
  67. ncbi Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse
    Reshma Singh
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 175:3663-73. 2005
    ..monocytogenes-based HER-2/neu vaccines in a murine model of breast cancer and also that the immunogenicity of self-Ags can be increased by fusion to LLO and delivery by L. monocytogenes revealing subdominant epitopes...
  68. ncbi Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
    Nobuaki Suzuki
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Int J Cancer 98:45-50. 2002
    ..Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients...
  69. pmc RNA helicase A interacts with dsDNA and topoisomerase IIalpha
    Kai Zhou
    Department of Biochemistry and Molecular Biology, Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, Newark, NJ 07013, USA
    Nucleic Acids Res 31:2253-60. 2003
    ..The putative role of RHA-topoisomerase IIalpha complex in RNA polymerase II-mediated transcription is discussed...
  70. pmc Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays
    Madhumita Chatterjee
    Program in Molecular Biology and Human Genetics, Barbara Ann Karmanos Cancer Institute, Wayne State University, 110 East Warren, Detroit, MI 48201, USA
    Cancer Res 66:1181-90. 2006
    ..Further work with larger panels of antigens should provide a comprehensive set of markers with sufficient sensitivity and specificity suitable for clinical testing in high-risk populations...
  71. pmc The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development
    Krasimir Slanchev
    Georges Koehler Laboratory, Max Planck Institute of Immunobiology, Freiburg, Germany
    PLoS Genet 5:e1000563. 2009
    ..In addition, EpCAM is required for the interaction of the epithelia with underlying cell layers...
  72. ncbi Direct integrin alphavbeta6-ERK binding: implications for tumour growth
    Nuzhat Ahmed
    Gynaecological Cancer Research Centre, The Royal Women s Hospital, Melbourne and University of Melbourne, Melbourne, Australia
    Oncogene 21:1370-80. 2002
    ..The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment...
  73. ncbi Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance
    Gang Zhou
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    J Immunol 178:2155-62. 2007
    ..Instead, induction of Ag-specific regulatory cells from naive cells is intrinsically influenced by the tumor microenvironment and the presence of tumor Ag...
  74. ncbi Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target
    Christian Potter
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford, UK
    Cell Cycle 3:164-7. 2004
    ..As it is commonly expressed in tumours with the worst prognosis it is a potential target for therapy...
  75. ncbi Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer
    Niels Reinmuth
    Department of Medicine, Westfalische Wilhelms Universitat, 48129, Munster, Germany
    Lung Cancer 36:265-70. 2002
    ....
  76. ncbi Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis
    Ashraf J Abusamra
    London Health Science Centers, London, Ontario, Canada
    Blood Cells Mol Dis 35:169-73. 2005
    ..Addition of anti-FasL antibody blocked the apoptosis induction by tumor exosomes. This study suggests that induction of T-cell apoptosis by tumor-derived exosomes appears to be a novel mechanism of tumor immune evasion...
  77. ncbi Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR
    Sachiko Okamoto
    Center for Cell and Gene Therapy, Takara Bio, Inc, Shiga, Japan
    Cancer Res 69:9003-11. 2009
    ..In consequence, the vector-transduced lymphocytes showed enhanced cytotoxic activity against antigen-expressing tumor cells. Therefore, our novel TCR gene therapy may open a new gate for effective immunotherapy in cancer patients...
  78. pmc Immunomic analysis of human sarcoma
    Sang Yull Lee
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:2651-6. 2003
    ..NY-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunotherapies...
  79. ncbi Immunosuppressive networks in the tumour environment and their therapeutic relevance
    Weiping Zou
    Tulane University Health Sciences Center, Section of Hematology and Medical Oncology, 1430 Tulane Avenue, New Orleans, Louisiana 70112 2699, USA
    Nat Rev Cancer 5:263-74. 2005
    ..Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity...
  80. ncbi Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritis
    Tetsuya Tomita
    Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
    Arthritis Rheum 46:373-8. 2002
    ..To investigate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) at sites of joint destruction in rheumatoid arthritis (RA) and to correlate it with the production of matrix metalloproteinases (MMPs)...
  81. ncbi Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer
    Fabrice Barlesi
    Faculty of Medicine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Service d Oncologie Thoracique, Marseille, Cedex 09, France
    Respir Med 98:357-62. 2004
    ..To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic factors in advanced stage non-small cell lung cancer (NSCLC) patients...
  82. pmc Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition
    Chi Ming Li
    Institute for Cancer Genetics, Columbia University, New York, New York, USA
    Am J Pathol 160:2181-90. 2002
    ..The WT-signature set also contained the Wnt receptor FZD7, the tumor antigen PRAME, the imprinted gene NNAT and the metastasis-associated transcription factor E1AF...
  83. pmc CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production
    G Zeng
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:3964-9. 2001
    ....
  84. ncbi Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma
    Andreas Mackensen
    Department of Hematology Oncology, University of Regensburg, Franz Josef Strauss Allee 11, D 93042 Regensburg, Germany
    J Clin Oncol 24:5060-9. 2006
    ..A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients...
  85. pmc Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
    Jian Ren
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 5:163-75. 2004
    ..These findings indicate that MUC1 attenuates the apoptotic response to DNA damage and that this oncoprotein confers resistance to genotoxic anticancer agents...
  86. ncbi Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 68:5955-64. 2008
    ..As such, our findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans...
  87. ncbi Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene
    Shelly R Gunn
    Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Leuk Res 33:1276-81. 2009
    ..Quantitative real-time PCR revealed that ZNF280A, ZNF280B, and PRAME mRNA expression was significantly lower in the 22q11 deletion cases compared to non-deleted cases...
  88. ncbi Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial
    Richard Harrop
    Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, United Kingdom
    Clin Cancer Res 12:3416-24. 2006
    ..The primary objectives were to assess the safety and immunogenicity of ascending doses of TroVax and to determine the biodistribution of the vector...
  89. ncbi Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9
    M J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Cancer Lett 150:155-64. 2000
    ..The coexpression pattern of these antigens provides a foundation for developing a polyvalent lung cancer vaccine...
  90. ncbi Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma
    Yoshihisa Fujita
    Department of General and Gastroenterological Surgery, Osaka Medical College, 2 7 Daigaku machi, Takatsuki City, Osaka 569 8686, Japan
    Cancer Lett 263:280-90. 2008
    ..We have identified an autoantibody against Hsp70 in ESCC patients. The proteomic approach implemented herein offers a powerful tool for identifying novel serum markers that may display clinical utility against cancer...
  91. pmc Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
    D C Saffran
    UroGenesys, Inc, 1701 Colorado Avenue, Santa Monica, CA 90404, USA
    Proc Natl Acad Sci U S A 98:2658-63. 2001
    ..These studies suggest PSCA as an attractive target for immunotherapy and demonstrate the therapeutic potential of anti-PSCA mAbs for the treatment of local and metastatic prostate cancer...
  92. pmc A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene
    S S Schneider
    Department of Pediatrics, Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 92:3147-51. 1995
    ..Further characterization of the region should determine whether the differential expression of the SCCA genes plays a causal role in development of more aggressive squamous cell carcinomas...
  93. pmc The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes
    O V Makarova
    Max Planck Institute for Biophysical Chemistry, Department of Cellular Biochemistry, Am Fassberg 11, D 37077 Gottingen, Germany
    EMBO J 20:2553-63. 2001
    ..Moreover, since both proteins contain an N-terminal RS domain, they could mediate the association of the tri-snRNP with pre-spliceosomes by interaction with members of the SR protein family...
  94. ncbi EpCAM expression in retinoblastoma: a novel molecular target for therapy
    Subramanian Krishnakumar
    Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, 18 College Road, Chennai 600006, Tamil Nadu, India
    Invest Ophthalmol Vis Sci 45:4247-50. 2004
    ..It was first determined whether EpCAM is expressed in retinoblastoma and then whether EpCAM reactivity correlates with tumor aggressiveness...
  95. pmc Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy
    Radoslav Chekerov
    Department of Obstetrics and Gynecology, Charite University Hospital, Campus Virchow, Berlin, Germany
    Neoplasia 8:38-45. 2006
    ..The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer...
  96. ncbi Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia
    Christina A Ortmann
    Klinik für Hämatologie, Zentrum für Konservative Onkologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany
    Ann Hematol 87:809-18. 2008
    ..Such a role is further supported by the observation that treatment of PRAME-negative cell lines U-937 and THP-1 with the demethylating agent 5'-Aza-2'dC resulted in a dose-related upregulation of PRAME expression...
  97. ncbi Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas
    David Hedley
    Division of Experimental Therapeutics and Department of Radiation Oncology, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 9:5666-74. 2003
    ..Recent studies suggest that carbonic anhydrase IX (CA IX), which is regulated via hypoxia-inducible factor 1, is a useful intrinsic marker of tumor hypoxia...
  98. ncbi Antibody-drug conjugates for cancer therapy
    Paul J Carter
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer J 14:154-69. 2008
    ..This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clinical trials for cancer therapy...
  99. pmc PRAME expression and clinical outcome of breast cancer
    M T Epping
    Division of Molecular Carcinogenesis and Centre for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
    Br J Cancer 99:398-403. 2008
    ..We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers...
  100. ncbi Bystander elimination of antigen loss variants in established tumors
    Michael T Spiotto
    Department of Pathology and the Committee on Immunology, The University of Chicago, Chicago, Illinois 60637, USA
    Nat Med 10:294-8. 2004
    ..These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells...
  101. ncbi Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion
    L M Shaw
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell 91:949-60. 1997
    ..The small G protein Rac is required downstream of PI3K for invasion. These studies define a mechanism by which the alpha6beta4 integrin promotes carcinoma invasion and invoke a novel function for PI3K signaling...

Research Grants82

  1. Mice with Human Dendritic Cells to Test Vaccine Potency
    A Palucka; Fiscal Year: 2004
    ..The experiments proposed here would lay ground for further use of SCID-hu/DCs mice to study other vaccines and demonstrate development of protective immunity upon in vivo rechallenge. ..
  2. Dendritic Cells and Breast Cancer Immunity
    A Palucka; Fiscal Year: 2004
    ..Overall, this proposal will permit us to demonstrate that efficient breast cancer immunity can be generated and used to reject the tumor thus permitting development of novel treatment modalities in breast cancer. ..
  3. VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ....
  4. Molecular Dissection of T Cell Anergy
    Thomas Gajewski; Fiscal Year: 2005
    ..Ultimately, a complete understanding of the anergic state on the molecular level should guide the development of novel pharmacologic therapies to promote or reverse peripheral tolerance in vivo. ..
  5. Technologies To Block Gene Expression in Normal T Cells
    Thomas Gajewski; Fiscal Year: 2003
    ..abstract_text> ..
  6. DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER
    Lawrence Fong; Fiscal Year: 2003
    ..The proposed studies will provide the foundation for simplified yet more potent DC targeted cancer immunotherapy for the future. ..
  7. Biochemical/Molecular Changes Upon Naive T Cell Priming
    Thomas Gajewski; Fiscal Year: 2005
    ....
  8. MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF
    Craig Slingluff; Fiscal Year: 2004
    ..abstract_text> ..
  9. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2009
    ....
  10. Vaccination with Regulatory T Cell Depletion
    Michael Morse; Fiscal Year: 2007
    ..Future studies will assess whether the greater magnitude and durability of the CEA-specific immune responses will translate into a long-term clinical benefit. [unreadable] [unreadable] [unreadable]..
  11. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2008
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  12. T Cell Responsiveness and Homeostasis in Anti-Tumor
    Thomas F Gajewski; Fiscal Year: 2010
    ..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
  13. DEXASOME BASED IMMUNOTHERAPY OF LUNG CANCER
    Michael Morse; Fiscal Year: 2002
    ..This clinical trial will form the background for further trials designed to demonstrate both immunology and clinical benefits of dexosome-based immunotherapy. ..
  14. Multi-Peptide/IL 12 Melanoma Vaccine
    Thomas Gajewski; Fiscal Year: 2006
    ..Understanding these mechanisms will illuminate the next level of intervention to develop to increase the clinical response to the immunotherapy of melanoma. [unreadable] [unreadable]..
  15. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  16. DGK in T Cell Regulation and Tolerance
    Thomas F Gajewski; Fiscal Year: 2010
    ..Ti U,0 ._0 ... ur tow 5a' c' OUP O-0 N-0 0-0 V,12 oar aux. :E, -'1 .., (gyp afl' coo COD m='(Dm o03-' _=c 3m03 l17 CDG'O COB 111 ..
  17. AFP-BASED PRIME-BOOST IMMUNOTHERAPY OF HCC
    LISA BUTTERFIELD; Fiscal Year: 2006
    ..These proposed studies will permit us to determine the immunological impact of a plasmid prime-adenoviral boost directed towards a self tumor antigen and to define mechanisms of antigen presentation. ..
  18. Polarized DC as Melanoma Vaccine: Phase 1 Evaluation
    Pawel Kalinski; Fiscal Year: 2006
    ....
  19. Green tea-mediated inhibition of aberrant DNA hypermethylation in prostate cancer
    ADAM KARPF; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  20. Dendritic Cell Vaccination During Lymphoid Reconstitution
    Jeffrey Weber; Fiscal Year: 2008
    ..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
  21. CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENT
    Leisha Emens; Fiscal Year: 2006
    ..abstract_text> ..
  22. Survival of CD4+CD25+ Regulatory T Cells
    Xiao Feng Yang; Fiscal Year: 2007
    ....
  23. B7-DC Cross-linking antibody immunotherapy
    Svetomir Markovic; Fiscal Year: 2008
    ..If successful, this "proof-of-principle" clinical trial will justify further development of B7-DC XAb as a cancer therapeutic with potential universal application for all malignant disorders. [unreadable] [unreadable] [unreadable]..
  24. HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA
    Jeffrey Weber; Fiscal Year: 2003
    ..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
  25. IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
    Jeffrey Weber; Fiscal Year: 2003
    ....
  26. Regulation of DC Activity by Memory and Effector CD8+ T Cells
    Pawel Kalinski; Fiscal Year: 2010
    ..abstract_text> ..
  27. Epigenetic regulation of cancer/germ-line antigen gene expression
    Adam R Karpf; Fiscal Year: 2010
    ..Furthermore, this study will provide key information relevant for understanding the outcome and improving the future design of clinical vaccine trials for the treatment of ovarian cancer. ..
  28. IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
    Jeffrey Weber; Fiscal Year: 2003
    ..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
  29. Defining Molecular Markers for Tumor Hypoxia
    QUYNH THU XUAN LE; Fiscal Year: 2010
    ..abstract_text> ..
  30. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  31. Tumor-reactive IgG in the diagnosis of ovarian cancer
    Douglas Taylor; Fiscal Year: 2005
    ..Ultimately, antigenic proteins, linked with histologic type and stage of disease, will be combined into the development of protein arrays to screen for circulating reactive IgG as an early diagnostic test. ..
  32. Immune Correlates of HSV-2 Disease Severity
    David Koelle; Fiscal Year: 2007
    ....
  33. EGFR activity in T cell-influenced glioma invasiveness & chemosensitivity
    Christopher Wheeler; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  34. TAG-72 Targeted Imaging for Cancer Detection
    Mary Rusckowski; Fiscal Year: 2007
    ..The agent developed in these studies could be of great benefit in the diagnosis of ovarian cancer, not only the primary site of disease, but possibly metastases as well. [unreadable] [unreadable] [unreadable]..
  35. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2007
    ..Importantly, the cloning of high affinity T cell receptors in retroviral vectors may be suitable for introduction into patient PBL for treatment of malignant melanoma. ..
  36. Thymocyte tuning after selection: mechanisms to avoid autoreactivity
    Terri M Laufer; Fiscal Year: 2010
    ..These experiments will define the mechanisms which regulate a critical thymic pathway that the immune system utilizes to avoid autoreactivity. ..
  37. Genetic Determinants of Bipolar Disorder
    Pamela Sklar; Fiscal Year: 2007
    ..An important dividend of this large study will be the expansion of the repository to include DNA data on relatives and on an independent sample of controls, thus facilitating future genetic studies. [unreadable] [unreadable]..
  38. Genome Integrative Pathway Modeling of Diabetic Atherosclerosis
    Jae K Lee; Fiscal Year: 2010
    ..Our GIPaM technology will also greatly enhance pathway discovery/modeling capability in other fields of the biomedical science. ..
  39. Autoantibody Signatures as Biomarkers of Interstitial Cystitis.
    Brian Liu; Fiscal Year: 2008
    ..abstract_text> ..
  40. CREB in Differentiation of Bronchial Mucous Cells
    Ja Seok Koo; Fiscal Year: 2007
    ..This application will address this hypothesis by determining the molecular mechanisms whereby CREB regulates normal and aberrant bronchial epithelial cell differentiation. ..
  41. Pigmentation and Diversity Conference
    ISABELLE LE POOLE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  42. Immunotherapeutic strategies for breast cancer
    YVONNE J PATERSON; Fiscal Year: 2010
    ....
  43. Tumor environmental CD4+CD25+ T cells
    Weiping Zou; Fiscal Year: 2006
    ..We hypothesize that MDC plus IL-2 are beneficial to tumor immunity by modifying the regulatory function ofCD4 + Tr cells. We predict that MDC plus IL-2, not MDC alone may be a strategy for treating cancer patients. ..
  44. Haplotype and Expression Mapping of Prepulse Inhibition
    Pamela Sklar; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  45. IMMUNOLOGICAL MECHANISM OF INFLAMMATION IN UVEITIS & EAE
    Grazyna Adamus; Fiscal Year: 2001
    ..3) Examine the role of cytokines and chemokines in the recruitment of cell to the eye in primary and recurrent uveitis associated with EAE after immunization of Lewis rats with MBP. ..
  46. Novel Immunotherapy for the treatment of cervical cancer
    Vafa Shahabi; Fiscal Year: 2005
    ..In addition, this technology can be applied to other cancers and infectious diseases, projects that are in preclinical development. ..
  47. Intradermal vaccinia:T-cell specificity and skin homing
    David Koelle; Fiscal Year: 2005
    ..2) Measure E-selectin binding by vaccinia-specific CD8 cells, and 2.3) Compare CLA and E-selectin binding by vaccinia-specific T-cells in recent and distant vaccines. ..
  48. Rapid Immunoassays for Detecting Pathogenic Bacteria
    Michael Wilson; Fiscal Year: 2004
    ..EIC has a commercial path for assay technology through in-house manufacturing, sale of electrochemical assays and hand-held assay readers, and out-licensing of our multianalyte immunoassay technology. ..
  49. INCREASE/gp120 IMMUNOGENICITY/LINKED ALPHA-GAL EPITOPES
    Uri Galili; Fiscal Year: 2005
    ..We will then also collaborate with a group studying immune responses in monkeys to determine the efficacy of this vaccine in a primate model. ..
  50. BIOCHEMISTRY OF UTERINE HEPARAN SULFATE RECEPTORS
    Daniel Carson; Fiscal Year: 2006
    ..In addition, we will examine the role(s) that HIP/L29 plays in vivo using transgenic mouse models. ..
  51. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2006
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. [unreadable] [unreadable]..
  52. CONFOCAL MICROSCOPY SYSTEM
    Sergei Rudchenko; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  53. Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphoma
    Yvonne Paterson; Fiscal Year: 2006
    ..We will also have tested 3 possible adjuvants to enhance its delivery. This will set the stage for a Phase II proposal focused on preparations for entering clinical trials. [unreadable] [unreadable] [unreadable]..
  54. HSV Immunotherapeutic Vaccine
    David Koelle; Fiscal Year: 2005
    ....
  55. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
  56. MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION
    FRANK HODI; Fiscal Year: 2002
    ..Further identification of immunogenic antigens in melanoma offers promise for future therapies. ..
  57. A New Biomarker for Ovarian Cancer Detection
    Eleftherios Diamandis; Fiscal Year: 2003
    ..In this grant proposal, we describe further studies, which will examine in greater detail, the ability of a test for the amount of this protein in blood to correctly diagnose the presence of ovarian cancer. ..
  58. Monoclonal Antibody Therapy Induction of Adaptive Immunity
    Louis Weiner; Fiscal Year: 2008
    ..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. [unreadable] [unreadable] [unreadable]..
  59. Human Kallikrein 4 (hK4): A New Prostatic Biomarker?
    Eleftherios Diamandis; Fiscal Year: 2003
    ..If successful, our research will contribute to the development of new prostatic biomarkers and possibly, to better diagnosis which may lead to better clinical outcomes and reduced healthcare costs. ..
  60. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  61. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009
    ..abstract_text> ..
  62. IMMUNOGENICITY OF HIV PROTEINS DELIVERED BY LIVE VECTOR
    Yvonne Paterson; Fiscal Year: 2004
    ..These studies will start in year 2 of the proposal. The hypothesis of this aim is that the attenuated strains will as effective as wild-type Listeria in delivering SHIV antigens to the immune system. ..
  63. Bacterial vector vaccine: Her-2/neu expressing tumors
    Yvonne Paterson; Fiscal Year: 2005
    ..This work will demonstrate the utility of the L. monocytogenes-based vaccines, thus setting the stage for further development of a breast cancer therapeutic that can be used in humans. ..
  64. Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
    Louis M Weiner; Fiscal Year: 2010
    ..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..
  65. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2004
    ..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
  66. DC-CD4 interactions in Th2 differentiation
    Terri Laufer; Fiscal Year: 2006
    ..abstract_text> ..
  67. ERAB, A BETA, NEUROTOXICITY AND ALZHEIMERS DISEASE
    Shi Du Yan; Fiscal Year: 2003
    ..abstract_text> ..
  68. Phase 1b Active Immunotherapy with HER-2 Multi-epitope v
    Pravin Kaumaya; Fiscal Year: 2003
    ..abstract_text> ..
  69. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  70. STRUCTURE/CONFORMATION ASPECTS IN PEPTIDE VACCINES
    Pravin Kaumaya; Fiscal Year: 2001
    ....
  71. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2009
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  72. T cell diversity in the induction of autoimmunity
    Terri Laufer; Fiscal Year: 2006
    ..Understanding the requirements for T cell diversity and the interactions between "graft" T cells and host antigen presenting cells offers improved immunologic targets for preventing GVHD following bone marrow transplant. ..
  73. Progenitor Cell Dysfunction and Impaired Vasculogenesis*
    Michael Brownlee; Fiscal Year: 2008
    ..rational development of novel strategies to restore normal compensatory vasculogenesis in diabetes, thus preventing the poor outcome of cardiovascular events (Ml, stroke, amputation) associated with the disease [unreadable] [unreadable]..
  74. ENHANCING TUMOR VACCINES WITH CO-STIMULATORY MOLECULES
    Howard Kaufman; Fiscal Year: 2004
    ..This may have important implications for the future design of tumor vaccines in melanoma and other settings. ..
  75. INTRACELLULAR GLYCATION AND DIABETIC COMPLICATIONS
    Michael Brownlee; Fiscal Year: 2007
    ..Supershift experiments will use commercially availableantibodies. IP-westernsof cell extracts will be immunoblotted with antibodies to glyoxalase I-substrate-derived advanced glycationendproducts. ..
  76. INTRACELLULAR GLYCATION AND DIABETIC COMPLICATIONS
    Michael Brownlee; Fiscal Year: 2006
    ..Supershift experiments will use commercially available antibodies. IP-westerns of cell extracts will be immunoblotted with antibodies to glyoxalase I-substrate- derived advanced glycation endproducts. ..
  77. The Role of RAGE and EAE
    Shi Du Yan; Fiscal Year: 2005
    ....
  78. CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIES
    Pravin Kaumaya; Fiscal Year: 2003
    ..This construct is now being tested in an NCI funded Phase 1b Clinical Trial at the Ohio State University. The result of this study may provide insight for the development of peptide vaccines against other tumor-associated antigens. ..
  79. Peptide Therapeutic Approaches for Immune Tolerance
    Pravin Kaumaya; Fiscal Year: 2003
    ..abstract_text> ..
  80. BD Biosciences FACS Canto Flow Cytometer
    LAWRENCE LAMB; Fiscal Year: 2006
    ..The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials. [unreadable] [unreadable]..
  81. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2006
    ..abstract_text> ..